JTX 2134
Alternative Names: JTX-2134Latest Information Update: 09 May 2023
At a glance
- Originator Jounce Therapeutics
- Developer Concentra Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Leukocyte immunoglobulin-like receptor B1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 May 2023 Preclinical trials in Cancer in USA (Parenteral) (Jounce Therapeutics pipeline, May 2023)
- 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences